Lucid Diagnostics closes $16.1M public offering of 14.4M shares at $1.20/share

Lucid Diagnostics Inc.

Closed sale of 14,375,000 shares of common stock at $1.20/share; underwriters' option exercised in full.
Net proceeds expected to be approximately $16.1 million after underwriting discounts and expenses.
Proceeds to be used for working capital and general corporate purposes.
Canaccord Genuity acted as sole bookrunner; Maxim Group as co-manager of the offering.
Offering made under existing shelf registration statement S-3 effective Dec 6, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.